Factor 8 Hemlibra denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for factor 8 hemlibra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Limits the Quantity of Hemlibra — and Why You Can Appeal

Hemlibra (emicizumab-kxwh) is a subcutaneous prophylactic agent administered on a regular schedule. Aetna's quantity limits for Hemlibra are typically tied to approved dosing intervals and body-weight-based calculations established in the FDA-approved prescribing information. A quantity-limit denial usually means the quantity requested exceeds what the plan's system calculates as appropriate based on the patient's documented weight and the approved dosing interval — or the prescribing interval differs from the one Aetna's policy defaults to.

Before filing a formal appeal, confirm whether this is a calculation discrepancy (the most common cause) or a policy disagreement about which dosing interval is appropriate for this patient.

## Why This Denial Is Appealable

The FDA-approved prescribing information for Hemlibra includes multiple dosing schedules. If the prescriber has selected an approved interval that results in a quantity Aetna's system does not anticipate, the denial is an administrative mismatch, not a clinical judgment. The prescriber's choice of dosing schedule — when within the FDA-approved label — is a medical decision that the plan cannot override solely on the basis of a quantity-limit rule.

## Federal Appeal Framework

• ERISA §503 (self-funded plans): Full-and-fair review; file within 180 days of the denial notice.
• ACA §2719 (fully-insured plans): Independent external review after internal exhaustion; typically within four months of the final internal denial.
• Expedited review: If inadequate supply creates an imminent bleed risk, request expedited review — typically 72-hour resolution.

## Concrete Appeal Steps and Timeline

1. Obtain the denial notice confirming the quantity-limit basis. 2. Confirm the prescribed quantity and dosing interval against the FDA-approved prescribing information. 3. Request Aetna's quantity-limit policy for Hemlibra, including the dosing-interval assumptions used. 4. Identify the specific discrepancy between the prescription and the plan's calculation. 5. File the internal appeal with a prescriber letter and supporting documentation. 6. If denied internally, escalate to external review within four months.

## Documentation to Gather

• Prescription and dosing rationale: The exact prescribed quantity, dosing interval, and the prescriber's clinical rationale for the selected schedule.
• Patient weight documentation: Current body weight from the chart, as quantity calculations for Hemlibra are weight-based.
• FDA prescribing information: The approved dosing schedules for Hemlibra, confirming the prescribed interval is within label.
• Prescriber letter: The hematologist should explain the selected dosing interval, why it is medically appropriate for this patient, and that the resulting quantity is consistent with the FDA-approved label.
• Diagnosis and treatment history: Hemophilia A diagnosis with inhibitor status; prior treatment outcomes.

## Criteria-Mapping Structure

Obtain Aetna's quantity-limit policy and the specific calculation it applied. Show the arithmetic: patient weight × approved dose per the FDA label × selected dosing interval = requested quantity. If the plan used a different dosing interval assumption, identify it explicitly and explain why the prescriber's selected interval is medically appropriate for this patient. This calculation-level detail resolves most Hemlibra quantity-limit disputes at the internal appeal stage.